MAST-CELL PROCARBOXYPEPTIDASE-A - MOLECULAR MODELING AND BIOCHEMICAL-CHARACTERIZATION OF ITS PROCESSING WITHIN SECRETORY GRANULES

Citation
Eb. Springman et al., MAST-CELL PROCARBOXYPEPTIDASE-A - MOLECULAR MODELING AND BIOCHEMICAL-CHARACTERIZATION OF ITS PROCESSING WITHIN SECRETORY GRANULES, The Journal of biological chemistry, 270(3), 1995, pp. 1300-1307
Citations number
53
Categorie Soggetti
Biology
ISSN journal
00219258
Volume
270
Issue
3
Year of publication
1995
Pages
1300 - 1307
Database
ISI
SICI code
0021-9258(1995)270:3<1300:MP-MMA>2.0.ZU;2-6
Abstract
Previously, we characterized murine mast cell procarboxypeptidase A (M C-proCPA) as an inactive zymogen, To investigate the mechanisms for th is lack of enzymatic activity and the processing of the zymogen to the active form, we now have performed molecular modeling of the tertiary structure of murine MC-proCPA based on the x-ray crystallographic str uctures of porcine pancreatic procarboxypeptidases A and B. Our model predicts that MC-proCPA retains a high degree of structural similarity to its pancreatic homologues, The globular propeptide physically bloc ks access to the fully formed active site of the catalytic domain and contains a salt bridge to the substrate-binding region that precludes docking of even small substrates, Based on consideration of the predic ted tertiary structure and charge field characteristics of the model, the activation site (between Glu(A94) and Ile(1)) appears to be highly exposed even after MC-proCPA binds to secretory granule proteoglycans , Based on the steady-state levels of MC-proCPA versus IMC-CPA, cycloh eximide inhibition of protein synthesis, and brefeldin A blockage of p rotein sorting, we show that MC-proCPA is processed rapidly in murine mast cell line KiSV-MC14 with a half-life of 26 +/- 5 min (mean +/- S. D., n = 3), and the processing occurs within the secretory granules, T he enzyme responsible for this processing may be a thiol protease sinc e treatment of the KiSV-MC14 with 200 mu M E-64d, a selective thiol-pr otease inhibitor, increases MC-proCPA by 2.7 +/- 0.2-fold (mean +/- S. D., n = 3) within 6 h of application.